Determinants of low-density lipoprotein cholesterol goal attainment: Insights from the CEPHEUS Pan-Asian Survey

Journal of the Chinese Medical Association

Volumn 77, Issue 2, 2014, Pages 61-67

  Wang, Ko Fan ^a   Chang, Chun Chin ^b   Wang, Kang Ling ^b,c   Wu, Cheng Hsueh ^b,c   Chen, Lung Ching ^c,d   Lu, Tse Min ^b,c   Lin, Shing Jong ^b,c   Chiang, Chern En ^b,c  

^a TAIPEI HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Cardiovascular disease prevention; Epidemiology; Hypercholesterolemia; Low density lipoprotein cholesterol; Statins

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ABDOMINAL OBESITY; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; GOAL ATTAINMENT; HEALTH SURVEY; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; METABOLIC SYNDROME X; TAIWAN; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASE PREVENTION; EPIDEMIOLOGY; HYPERCHOLESTEROLEMIA; LOW-DENSITY LIPOPROTEIN CHOLESTEROL; STATINS;

AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DATA COLLECTION; DIABETES COMPLICATIONS; FEMALE; GOALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; METABOLIC SYNDROME X; PROSPECTIVE STUDIES; TAIWAN;

EID: 84892970862     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/j.jcma.2013.10.013     Document Type: Article

References (33)

1. Roger V.L., Go A.S., Lloyd-Jones D.M., Benjamin E.J., Berry J.D., Borden W.B., et al. Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012, 125:188-197.
2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22. Heart Protection Study Collaborative Group.
3. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
4. Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., Bhala N., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
5. Mihaylova B., Emberson J., Blackwell L., Keech A., Simes J., Barnes E.H., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590.
6. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004, 44:720-732.
7. Malik S., Lopez V., Chen R., Wu W., Wong N.D. Undertreatment of cardiovascular risk factors among persons with diabetes in the United States. Diabetes Res Clin Pract 2007, 77:126-133.
8. Nag S.S., Daniel G.W., Bullano M.F., Kamal-Bahl S., Sajjan S.G., Hu H., et al. LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO. J Manag Care Pharm 2007, 13:652-663.
9. Kotseva K., Wood D., De Backer G., De Bacquer D., Pyorala K., Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009, 373:929-940.
10. Hermans M.P., Castro Cabezas M., Strandberg T., Ferrieres J., Feely J., Elisaf M., et al. Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin 2010, 26:445-454.
11. Waters D.D., Brotons C., Chiang C.W., Ferrieres J., Foody J., Jukema J.W., et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009, 120:28-34.
12. Parris E.S., Lawrence D.B., Mohn L.A., Long L.B. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 2005, 28:595-599.
13. Daskalopoulou S.S., Doonan R.J., Mikhailidis D.P. Undertreatment of hypercholesterolemia. Curr Med Res Opin 2010, 26:439-443.
14. Baessler A., Fischer M., Huf V., Mell S., Hengstenberg C., Mayer B., et al. Failure to achieve recommended LDL cholesterol levels by suboptimal statin therapy relates to elevated cardiac event rates. Int J Cardiol 2005, 101:293-298.
15. Kim B.K., Kim D.W., Oh S., Yoon S.J., Park S., Jeon D.W., et al. Impact of the attainment of current recommended low-density lipoprotein cholesterol goal of less than 70 mg/dL on clinical outcomes in very high-risk patients treated with drug-eluting stents. Coron Artery Dis 2010, 21:182-188.
16. Pearson T.A., Laurora I., Chu H., Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000, 160:459-467.
17. Kim H.S., Wu Y., Lin S.J., Deerochanawong C., Zambahari R., Zhao L., et al. Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study. Curr Med Res Opin 2008, 24:1951-1963.
18. Park J.E., Chiang C.E., Munawar M., Pham G.K., Sukonthasarn A., Aquino A.R., et al. Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey. Eur J Prev Cardiol 2012, 19:781-794.
19. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421. National Cholesterol Education Program (NCEP) Expert Panel on Detection.
20. Hsuan C.F., Lee T.L., Chang H.L., Tseng W.K., Wu C.C. A retrospective study of statin use and its effectiveness in Taiwanese. Acta Cardiol Sin 2009, 25:18-25.
21. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001, 22:554-572. EUROASPIRE II Study Group.
22. Reiner Z., Catapano A.L., De Backer G., Graham I., Taskinen M.R., Wiklund O., et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818.
23. Ho K.T., Chin K.W., Ng K.S., Alemao E., Rajagopalan S., Yin D. The A-SACT (Achievement in Singapore of Cholesterol Targets) study in patients with coronary heart disease. Am J Cardiovasc Drugs 2006, 6:383-391.
24. Yan A.T., Yan R.T., Tan M., Hackam D.G., Leblanc K.L., Kertland H., et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 2006, 119:676-683.
25. Goodman S.G., Langer A., Bastien N.R., McPherson R., Francis G.A., Genest J.J., et al. Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS). Can J Cardiol 2010, 26:e330-e335.
26. Lin Y.C., Yang C.C., Chen Y.J., Peng W.C., Li C.Y., Hwu C.M. Utilization of statins and aspirin among patients with diabetes and hyperlipidemia: Taiwan, 1998-2006. J Chin Med Assoc 2012, 75:567-572.
27. Avogaro A., Guida P., Giorda C., Mannucci E., Medea G., Comaschi M., et al. The under-use of statin in type 2 diabetic patients attending diabetic clinics in Italy. Nutr Metab Cardiovasc Dis 2007, 17:32-40.
28. Shyu K.G., Wu C.J., Mar G.Y., Hou J.Y., Li A.H., Wen M.S., et al. Clinical characteristics, management and in-hospital outcomes of patients with acute coronary syndrome - observations from the Taiwan ACS full spectrum registry. Acta Cardiol Sin 2011, 27:135-144.
29. Munawar M., Hartono B., Rifqi S. Cholesterol goal attainment in hypercholesterolemia: CEPHEUS Indonesian survey. Acta Cardiol Sin 2013, 29:71-81.
30. LaRosa J.C. Means and ends of statins and low-density lipoprotein cholesterol lowering. J Am Coll Cardiol 2007, 50:419-420.
31. Jukema J.W., Cannon C.P., de Craen A.J., Westendorp R.G., Trompet S. The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol 2012, 60:875-881.
32. Wang K.L., Liu C.J., Chao T.F., Huang C.M., Wu C.H., Chen S.J., et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol 2012, 60:1231-1238.
33. Ridker P.M., Pradhan A., MacFadyen J.G., Libby P., Glynn R.J. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012, 380:565-571.